CCND2 and breast cancer: Evron and colleagues [22] reported that methylation analysis, with a three-gene marker panel (Cyclin D2, RAR-β and Twist), of DNA from the exfoliated cells in 56 DL samples from asymptomatic women at increased risk for developing breast cancer (Gail risk at least 1.7-fold) had a sensitivity of 67% and a specificity of 89% for the detection of severely atypical or malignant epithelial cells.